Stacy Enxing Seng

Stacy Enxing Seng was appointed to LivaNova’s Board in June 2019. She spent 25 years in the healthcare and medical technology industries, including serving in executive roles as the former President of Covidien Vascular Therapies and President of Covidien Peripheral Vascular. In 2010, Ms. Enxing Seng joined Covidien through the successful $2.6-billion acquisition of ev3 Incorporated, where she was a founding member and executive officer. Since 2016, she served as a venture partner with Lightstone Ventures, and an independent director for several healthcare and medical technology companies. She also held positions of increasing responsibility with SCIMED, Boston Scientific, American Hospital Supply and Baxter. From 2014 to 2019, she served on the boards of Solace Therapeutics, Claret Inc., Spirox Inc., FIRE 1 INC. and Go Red for Women and Minnesota – American Heart Association. Ms. Enxing Seng currently serves as Chairwoman of Cala Health Inc. and on the boards of Sonova Holding AG, Hill-Rom Holdings Inc., PreCardia Inc. and The Fogarty Institute for Innovation, an educational non-profit organization. Ms. Enxing Seng’s qualifications for service on the LivaNova Board include her broad experience and insights across strategy, marketing, sales, innovation, M&A and a variety of other medical device related areas.